Previous Page  13 / 43 Next Page
Information
Show Menu
Previous Page 13 / 43 Next Page
Page Background www.revisionesencancer.com

1 )

“Tratamiento médico del cáncer en el año 2019”

Organiza:

6 , 7 y 8 d e f e b r e r o 2 0 1 9

NH Collection Eurobuilding

M A D R I D

www.revisionesencancer.com

C O O R D I N A D O R E S C I E N T Í F I C O S :

Eduardo Díaz-Rubio

Enrique Aranda Aguilar

Enrique Grande Pulido

Ana Lluch Hernández

Pedro Pérez Segura

Mariano Provencio Pulla

¿Son todos los test genómicos iguales?

PROLIFERATION

Ki-67

STK15

Survivin

Cyclin B1

MYBL2

ESTROGEN

ER

PR

Bcl2

SCUBE2

INVASION

Stromelysin 3

Cathepsin L2

HER2

GRB7

HER2

BAG1

GSTM1

REFERENCE

Beta-actin

GAPDH

RPLPO

GUS

TFRC

CD68

16 Cancer and 5 Reference Genes From 3 Studies

Category

RS (0 -100)

Low risk

RS <18

Int risk

RS 18 - 30

High risk

RS ≥ 31

Paik et al. N Engl J Med. 2004;351:2817-2826.

RS = + 0.47 x HER2 Group Score

- 0.34 x ER Group Score

+ 1.04 x Proliferation Group Score

+ 0.10 x Invasion Group Score

+ 0.05 x CD68

- 0.08 x GSTM1

- 0.07

x BAG1